1
|
Dykstra M, Thompson J, Aldous J, Jiang S, Hughes T, Hayman J, Dragovic A, Shah J, Chang A, Speers C, Sabel M, Dossett L, Schipper M, Jagsi R. The Effect of Wire Versus Magnetic Seed Localization on Lumpectomy Cavity Size. Pract Radiat Oncol 2024; 14:e255-e263. [PMID: 38161002 DOI: 10.1016/j.prro.2023.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 11/29/2023] [Accepted: 12/01/2023] [Indexed: 01/03/2024]
Abstract
PURPOSE Our purpose was to assess whether an association exists between surgical localization technique and lumpectomy cavity size on radiation therapy planning computed tomography (CT) scan. METHODS AND MATERIALS A single-institution retrospective review was conducted of women undergoing breast conserving surgery with wire or magnetic seed guided lumpectomy followed by adjuvant radiation therapy from 2018 to 2021. Patients of a surgeon only performing 1 localization technique or undergoing bracketed localization were excluded. The primary outcome was lumpectomy cavity size on simulation CT. Confounding due to imbalance in patient and tumor factors was addressed with overlap weights derived from a propensity score analysis and used in a weighted multivariable analysis. Secondary outcomes included positive margins, total pathologic volume, boost delivery, and boost modality. RESULTS Of 617 women who received lumpectomy during the study period, 387 were included in final analysis. Tumors of patients undergoing seed localization were more likely unifocal, assessable by ultrasound, and smaller. Seed use rates ranged from 27.7% to 70.7% per surgeon. There was no difference in positive margins (6.4 vs 5.4%, P = .79) or second surgeries (9.4 vs 8.1%, P = .79) between groups. Close margin rates were similar for ductal carcinoma in situ (P = .35) and invasive carcinoma (P = .97). In unadjusted bivariable analyses, wire localization was associated with larger total pathology volume (P = .004), but localization technique showed no association with CT cavity volume (P = .15). After adjusting for potentially confounding variables, multivariable analysis failed to show an association between localization technique and either CT cavity (P = .35) or total path volume (P = .08). There was no difference in indicated-boost delivery (P = .15) or electron boost (P = .14) by localization technique. CONCLUSIONS There was no significant difference in CT cavity size by localization technique, suggesting choice between surgical techniques does not impede radiation therapy boost delivery.
Collapse
Affiliation(s)
- Michael Dykstra
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Jessica Thompson
- Department of Surgery, Division of Surgical Oncology, Corewell Health Medical Group, Grand Rapids, Michigan
| | - Jessica Aldous
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Shannon Jiang
- Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri
| | - Tasha Hughes
- Department of Surgery, Division of Surgical Oncology, University of Michigan, Ann Arbor, Michigan
| | - James Hayman
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Aleksandar Dragovic
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Jennifer Shah
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Alfred Chang
- Department of Surgery, Division of Surgical Oncology, University of Michigan, Ann Arbor, Michigan
| | - Corey Speers
- Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio
| | - Michael Sabel
- Department of Surgery, Division of Surgical Oncology, University of Michigan, Ann Arbor, Michigan
| | - Lesly Dossett
- Department of Surgery, Division of Surgical Oncology, University of Michigan, Ann Arbor, Michigan
| | - Matthew Schipper
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | - Reshma Jagsi
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
| |
Collapse
|
2
|
Hadžikadić-Gušić L, Cerić T, Marijanović I, Iljazović E, Koprić D, Zorlak A, Tanović M, Mekić-Abazović A, Šišić I, Delić U, Mustedanagić-Mujanović J, Aginčić A, Bećiragić E, L Greene F. Guidelines for breast cancer management in Bosnia and Herzegovina. BIOMOLECULES AND BIOMEDICINE 2023; 23:2-14. [PMID: 35880400 PMCID: PMC9901905 DOI: 10.17305/bjbms.2022.7504] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 07/12/2022] [Indexed: 02/08/2023]
Abstract
Breast cancer is the most common cancer among women. In Bosnia and Herzegovina, accurate data on the status of breast cancer are lacking due to the absence of a central registry. Multiple international guidelines imply that institutions that monitor breast cancer patients should have optimal therapeutic options for treatment. In addition, there have been several international consensus guidelines written on the management of breast cancer. Application of consensus guidelines has previously been demonstrated to have a positive influence on breast cancer care. The importance of specialty breast centers has previously been reported. As part of the 2021 Bosnian-Herzegovinian American Academy of Arts and Sciences (BHAAAS) conference in Mostar, a round table of multidisciplinary specialists from Bosnia and Herzegovina and the diaspora was held. All were either members of BHAAAS or regularly participate in collaborative projects. The focus of the consortium was to write the first multidisciplinary guidelines for the general management of breast cancer in Bosnia and Herzegovina. Guidelines were developed for each area of breast cancer treatment and management. These guidelines will serve as a resource for practitioners managing breast cancer in the Bosnia and Herzegovina region. This might also be of benefit to the ministry of health and any future investors interested in developing breast cancer care policies in this region of the world.
Collapse
Affiliation(s)
- Lejla Hadžikadić-Gušić
- Department of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA,Correspondence to Lejla Hadžikadić-Gušić:
| | - Timur Cerić
- Department of Medical Oncology, University Clinical Center, Sarajevo, Bosnia and Herzegovina
| | - Inga Marijanović
- Clinic of Oncology, University Clinical Hospital, Mostar, Bosnia and Herzegovina
| | - Ermina Iljazović
- Department of Pathology, University Clinical Center, Tuzla, Bosnia and Herzegovina
| | - Dijana Koprić
- Department of Medical Oncology and Radiation Oncology, University Clinical Center, Tuzla, Bosnia and Herzegovina
| | - Anela Zorlak
- Genetics Counseling, Genetika, Sarajevo, Bosnia and Herzegovina
| | - Mahira Tanović
- Plastic and Reconstructive Surgery, Advanced Plastic Surgery of North Shore, NY, USA
| | - Alma Mekić-Abazović
- Department of Medical Oncology, Kanton Hospital Zenica, Zenica, Bosnia and Herzegovina
| | - Ibrahim Šišić
- Department of Medical Oncology, Kanton Hospital Zenica, Zenica, Bosnia and Herzegovina
| | - Una Delić
- Department of Radiology, University Clinical Center, Sarajevo, Bosnia and Herzegovina
| | | | - Alija Aginčić
- Plastic and Reconstructive Surgery, Center for Aesthetic Surgery, Nasa Mala Klinika (Our Little Clinic), Sarajevo, Bosnia and Heregovina
| | - Edin Bećiragić
- Department of Surgery, Dr. Abdulah Nakas General Hospital, Sarajevo, Bosnia and Herzegovina
| | | |
Collapse
|
3
|
Impact of Regional Nodal Irradiation and Hypofractionated Whole-Breast Radiation on Long-Term Breast Retraction and Poor Cosmetic Outcome in Breast Cancer Survivors. Clin Breast Cancer 2020; 20:e75-e81. [DOI: 10.1016/j.clbc.2019.08.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 07/12/2019] [Accepted: 08/23/2019] [Indexed: 11/22/2022]
|
4
|
A novel technique for treating deep seated breast cavity boosts. Med Dosim 2019; 45:149-152. [PMID: 31548101 DOI: 10.1016/j.meddos.2019.08.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 08/06/2019] [Accepted: 08/22/2019] [Indexed: 11/21/2022]
Abstract
Breast boost irradiation is an integral component to the standard of care for early staged breast cancer. The use of reduced tangents is common for deep seating tumor bed; however, reduced tangents result in non-conformal plans delivering prescription dose to large volumes of breast tissue. To improve conformity, a novel technique of integrating a single conformal arc with reduced tangents has been developed. With this technique, a conformal arc was placed between a pair of reduced tangents to better conform the prescription dose to the target volume. This new technique improves the conformity but was also shown to potentially increase max dose to nearby critical structures, such as the heart, due to exit dose from the arc. This tangent and arc technique has been implemented at our clinic in cases where the exit dose is not critical to the heart.
Collapse
|
5
|
Dewan A, Chufal KS, Dewan AK, Pahuja A, Mehrotra K, Singh R, Chaudhary RL, Suresh T, Mishra M, Sundari AV, Bommera S, Narang R, Pathak P, Mitra S, Sharma SK, Gairola M. Simultaneous integrated boost by Intensity Modulated Radiotherapy (SIB-IMRT) in patients undergoing breast conserving surgery – A clinical and dosimetric perspective. J Egypt Natl Canc Inst 2018; 30:165-171. [DOI: 10.1016/j.jnci.2018.10.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2018] [Revised: 10/16/2018] [Accepted: 10/17/2018] [Indexed: 01/25/2023] Open
|
6
|
Youssef A, Stanford J. Hypofractionation Radiotherapy vs. Conventional Fractionation for Breast Cancer: A Comparative Review of Toxicity. Cureus 2018; 10:e3516. [PMID: 30648051 PMCID: PMC6318139 DOI: 10.7759/cureus.3516] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The use of postoperative radiation therapy after breast-conserving surgery was longstanding standard practice. The treatment protocol used a standard fractionation of 50 Gy in 25 fractions plus a boost. Recently, the hypofractionation approach has gained support based on Canadian and English studies that claimed equal tumor control and similar toxicity to the standard protocol. We conducted a review of the literature of hypofractionation studies and compared the reported toxicity with the general literature. We placed special emphasis on breast fibrosis after hypofractionation versus standard fractionation. We found a striking difference in the breast toxicity reported by the hypofractionation literature regarding breast fibrosis as compared to standard fractionation. Breast fibrosis should be explored further via additional studies and discussed with potential breast-conserving surgery patients.
Collapse
Affiliation(s)
- Ashraf Youssef
- Radiation Oncology, Geisinger / Holy Spirit, Mechanicsburg, USA
| | - Jason Stanford
- Radiation Oncology, Geisinger / Holy Spirit, Mechanicsburg, USA
| |
Collapse
|
7
|
Bautista Hernandez MY, Lujan Castilla PJ, Quézada Bautista AA. Hypofractionation with concomitant boost using intensity-modulated radiation therapy in early-stage breast cancer in Mexico. Rep Pract Oncol Radiother 2018; 23:276-283. [PMID: 30090027 DOI: 10.1016/j.rpor.2018.06.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Accepted: 06/23/2018] [Indexed: 10/28/2022] Open
Abstract
Aim To evaluate whether hypofractionation with integrated boost to the tumour bed using intensity-modulated radiation therapy is an acceptable option and to determine whether this treatment compromises local control, toxicity and cosmesis. Background Retrospective studies have demonstrated that patients who are treated with HF and integrated boost experience adequate local control, a dosimetric benefit, decreased toxicity and acceptable cosmesis compared with conventional fractionation. Materials and methods A retrospective, observational and longitudinal study was conducted from January 2008 to June 2015 and included 34 patients with breast cancer (stage 0-II) who were undergoing conservative surgery.The prescribed doses were 45 Gy in 20 fractions (2.25 Gy/fraction) to the breast and 56 Gy in 20 fractions (2.8 Gy/fraction) to the tumour bed. Results Thirty-four patients were included. The mean follow-up was 49.29 months, and the mean age was 52 years. The mean percentage of PTV from the mammary region that received 100% of the prescribed dose was 97.89% (range 95-100), and the mean PTV percentage of the tumour bed that received 100% of the dose was 98% (95-100).The local control and the overall survival were 100%, and the cosmesis was good in 82% of the patients. Grade 1 acute toxicity was present in 16 patients (47%), and grade 1 chronic toxicity occurred in 6 cases (18%). Conclusion The results of the present study demonstrate that hypofractionation with integrated boost using intensity-modulated radiation therapy is an acceptable option that provides excellent local control and low toxicity.
Collapse
|
8
|
Jong W, Ung N, Tiong A, Rosenfeld A, Wong J. Characterisation of a MOSFET-based detector for dose measurement under megavoltage electron beam radiotherapy. Radiat Phys Chem Oxf Engl 1993 2018. [DOI: 10.1016/j.radphyschem.2017.11.021] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Wang S, Ma X, Hong X, Cheng Y, Tian Y, Zhao S, Liu W, Tang Y, Zhao R, Song L, Teng Z, Lu G. Adjuvant Photothermal Therapy Inhibits Local Recurrences after Breast-Conserving Surgery with Little Skin Damage. ACS NANO 2018; 12:662-670. [PMID: 29271636 DOI: 10.1021/acsnano.7b07757] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Adjuvant treatments following breast-conserving surgery (BCS) are essential to reduce the risk of local recurrences in patients with breast cancer. However, current adjuvant treatments are based on ionizing radiation, which brings radiation-induced damage and amplifies the risk of death. Here we explore the feasibility of using non-ionizing light to induce photothermal therapy as an adjuvant treatment to BCS. In an orthotopic breast cancer mice model, we demonstrate that adjuvant photothermal therapy (aPTT) decreases the incidence of local recurrences after BCS with no expense of cosmetic outcome. In comparison with conventional photothermal therapy, the technique used in aPTT provides more uniformly distributed light energy and less risk of skin burns and local recurrences. Overall, this work represents a departure from the traditional concept of using PTT as an alternative to surgery and reveals the potential of using PTT as an alternative to adjuvant radiation therapy, which is valuable especially for patients susceptible to radiation damage.
Collapse
Affiliation(s)
- Shouju Wang
- Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University , Nanjing 210002, P. R. China
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University , Nanjing 210093, P. R. China
| | - Xingqun Ma
- The Affiliated Bayi Hospital of Nanjing University of Chinese Medicine , Nanjing 210002, P. R. China
| | - Xuhao Hong
- Department of Physics, Nanjing University , Nanjing 210000, P. R. China
| | - Yingxia Cheng
- The Affiliated Bayi Hospital of Nanjing University of Chinese Medicine , Nanjing 210002, P. R. China
| | - Ying Tian
- Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University , Nanjing 210002, P. R. China
| | - Shuang Zhao
- Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University , Nanjing 210002, P. R. China
| | - Wenfei Liu
- Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University , Nanjing 210002, P. R. China
| | - Yuxia Tang
- Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University , Nanjing 210002, P. R. China
| | - Ruizhi Zhao
- Department of Physics, Nanjing University , Nanjing 210000, P. R. China
| | - Liang Song
- Research Laboratory for Biomedical Optics and Molecular Imaging, Shenzhen Key Laboratory for Molecular Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences , Shenzhen 518055, P. R. China
| | - Zhaogang Teng
- Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University , Nanjing 210002, P. R. China
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University , Nanjing 210093, P. R. China
| | - Guangming Lu
- Department of Medical Imaging, Jinling Hospital, School of Medicine, Nanjing University , Nanjing 210002, P. R. China
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University , Nanjing 210093, P. R. China
| |
Collapse
|
10
|
Lin JY, Bluebond-Langner R, Choi E, Cheston S, Nichols EM, Cohen RJ, Bentzen SM, Drogula C, Kesmodel S, Bellavance E, Rosenblatt P, Tkaczuk K, Slezak S, Feigenberg SJ. Effect of reduction mammoplasty on acute radiation side effects and use of lumpectomy cavity boosts. Pract Radiat Oncol 2017; 7:e299-e308. [DOI: 10.1016/j.prro.2017.01.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Revised: 01/02/2017] [Accepted: 01/05/2017] [Indexed: 10/20/2022]
|
11
|
Radiation-induced fibrosis in the boost area after three-dimensional conformal radiotherapy with a simultaneous integrated boost technique for early-stage breast cancer: A multivariable prediction model. Radiother Oncol 2017; 122:45-49. [DOI: 10.1016/j.radonc.2016.10.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2016] [Revised: 09/22/2016] [Accepted: 10/02/2016] [Indexed: 01/19/2023]
|
12
|
Hamilton DG, Bale R, Jones C, Fitzgerald E, Khor R, Knight K, Wasiak J. Impact of tumour bed boost integration on acute and late toxicity in patients with breast cancer: A systematic review. Breast 2016; 27:126-35. [PMID: 27113229 DOI: 10.1016/j.breast.2016.03.002] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Revised: 02/24/2016] [Accepted: 03/11/2016] [Indexed: 01/13/2023] Open
Abstract
The purpose of this systematic review was to summarise the evidence from studies investigating the integration of tumour bed boosts into whole breast irradiation for patients with Stage 0-III breast cancer, with a focus on its impact on acute and late toxicities. A comprehensive systematic electronic search through the Ovid MEDLINE, EMBASE and PubMed databases from January 2000 to January 2015 was conducted. Studies were considered eligible if they investigated the efficacy of hypo- or normofractionated whole breast irradiation with the inclusion of a daily concurrent boost. The primary outcomes of interest were the degree of observed acute and late toxicity following radiotherapy treatment. Methodological quality assessment was performed on all included studies using either the Newcastle-Ottawa Scale or a previously published investigator-derived quality instrument. The search identified 35 articles, of which 17 satisfied our eligibility criteria. Thirteen and eleven studies reported on acute and late toxicities respectively. Grade 3 acute skin toxicity ranged from 1 to 7% whilst moderate to severe fibrosis and telangiectasia were both limited to 9%. Reported toxicity profiles were comparable to historical data at similar time-points. Studies investigating the delivery of concurrent boosts with whole breast radiotherapy courses report safe short to medium-term toxicity profiles and cosmesis rates. Whilst the quality of evidence and length of follow-up supporting these findings is low, sufficient evidence has been generated to consider concurrent boost techniques as an alternative to conventional sequential techniques.
Collapse
Affiliation(s)
- Daniel George Hamilton
- Epworth Radiation Oncology Research Centre, Epworth Richmond, 32 Erin St, Richmond VIC 3121, Australia; Epworth Radiation Oncology, Epworth Richmond, 32 Erin St, Richmond VIC 3121, Australia.
| | | | - Claire Jones
- Epworth Radiation Oncology, Epworth Richmond, 32 Erin St, Richmond VIC 3121, Australia
| | - Emma Fitzgerald
- Epworth Radiation Oncology, Epworth Richmond, 32 Erin St, Richmond VIC 3121, Australia
| | - Richard Khor
- Austin Health, Austin Hospital, 145 Studley Road, Heidelberg VIC 3121, Australia
| | - Kellie Knight
- Department of Medical Imaging & Radiation Sciences, School of Biomedical Sciences, Faculty of Medicine, Nursing & Health Sciences, Monash University, Clayton VIC 3800, Australia
| | - Jason Wasiak
- Epworth Radiation Oncology Research Centre, Epworth Richmond, 32 Erin St, Richmond VIC 3121, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| |
Collapse
|
13
|
Meattini I, Guenzi M, Fozza A, Vidali C, Rovea P, Meacci F, Livi L. Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer. Breast Cancer 2016; 24:52-62. [DOI: 10.1007/s12282-016-0694-3] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 03/20/2016] [Indexed: 12/25/2022]
|
14
|
Bodilsen A, Bjerre K, Offersen BV, Vahl P, Amby N, Dixon JM, Ejlertsen B, Overgaard J, Christiansen P. Importance of margin width in breast-conserving treatment of early breast cancer. J Surg Oncol 2016; 113:609-15. [DOI: 10.1002/jso.24224] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Accepted: 02/28/2016] [Indexed: 11/11/2022]
Affiliation(s)
- Anne Bodilsen
- Department of Breast and Endocrine Surgery; Aarhus University Hospital; Aarhus Denmark
| | - Karsten Bjerre
- Danish Breast Cancer Cooperative Group; Copenhagen Denmark
| | | | - Pernille Vahl
- Department of Pathology; Aarhus University Hospital; Aarhus Denmark
| | - Nikolaj Amby
- Department of Oncology; Aarhus University Hospital; Aarhus Denmark
| | - J. Michael Dixon
- Breakthrough Research Unit Edinburgh Breast Unit; Western General Hospital; Edinburgh United Kingdom
| | - Bent Ejlertsen
- Danish Breast Cancer Cooperative Group; Copenhagen Denmark
- Department of Oncology; Copenhagen University Hospital; Rigshospitalet Copenhagen Denmark
| | - Jens Overgaard
- Department of Experimental Clinical Oncology; Aarhus University Hospital; Aarhus Denmark
| | - Peer Christiansen
- Department of Surgery P, Breast Surgery Unit; Aarhus University Hospital/Randers Regional Hospital; Aarhus Denmark
| |
Collapse
|
15
|
Bodilsen A, Bjerre K, Offersen BV, Vahl P, Ejlertsen B, Overgaard J, Christiansen P. The Influence of Repeat Surgery and Residual Disease on Recurrence After Breast-Conserving Surgery: A Danish Breast Cancer Cooperative Group Study. Ann Surg Oncol 2015; 22 Suppl 3:S476-85. [DOI: 10.1245/s10434-015-4707-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Indexed: 12/21/2022]
|
16
|
Smith S, Comins C. Radiographer-led breast boost localisation – A service evaluation study. Radiography (Lond) 2015. [DOI: 10.1016/j.radi.2014.08.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Smith BD. When Is Good Enough Really Good Enough? Defining the Role of Radiation in Low-Risk Ductal Carcinoma In Situ. J Clin Oncol 2015; 33:686-91. [DOI: 10.1200/jco.2014.59.4259] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
18
|
Plastaras JP, Berman AT, Freedman GM. Special Cases for Proton Beam Radiotherapy: Re-irradiation, Lymphoma, and Breast Cancer. Semin Oncol 2014; 41:807-19. [DOI: 10.1053/j.seminoncol.2014.10.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
19
|
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys 2014; 88:553-64. [PMID: 24521674 DOI: 10.1016/j.ijrobp.2013.11.012] [Citation(s) in RCA: 295] [Impact Index Per Article: 29.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Accepted: 11/06/2013] [Indexed: 02/06/2023]
Abstract
PURPOSE To convene a multidisciplinary panel of breast experts to examine the relationship between margin width and ipsilateral breast tumor recurrence (IBTR) and develop a guideline for defining adequate margins in the setting of breast conserving surgery and adjuvant radiation therapy. METHODS AND MATERIALS A multidisciplinary consensus panel used a meta-analysis of margin width and IBTR from a systematic review of 33 studies including 28,162 patients as the primary evidence base for consensus. RESULTS Positive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with a 2-fold increase in the risk of IBTR compared with negative margins. This increased risk is not mitigated by favorable biology, endocrine therapy, or a radiation boost. More widely clear margins than no ink on tumor do not significantly decrease the rate of IBTR compared with no ink on tumor. There is no evidence that more widely clear margins reduce IBTR for young patients or for those with unfavorable biology, lobular cancers, or cancers with an extensive intraductal component. CONCLUSIONS The use of no ink on tumor as the standard for an adequate margin in invasive cancer in the era of multidisciplinary therapy is associated with low rates of IBTR and has the potential to decrease re-excision rates, improve cosmetic outcomes, and decrease health care costs.
Collapse
MESH Headings
- Age Factors
- Antineoplastic Agents/therapeutic use
- Breast Neoplasms/drug therapy
- Breast Neoplasms/pathology
- Breast Neoplasms/radiotherapy
- Breast Neoplasms/surgery
- Carcinoma in Situ/drug therapy
- Carcinoma in Situ/pathology
- Carcinoma in Situ/radiotherapy
- Carcinoma in Situ/surgery
- Carcinoma, Lobular/drug therapy
- Carcinoma, Lobular/pathology
- Carcinoma, Lobular/radiotherapy
- Carcinoma, Lobular/surgery
- Chemotherapy, Adjuvant/methods
- Chemotherapy, Adjuvant/standards
- Consensus
- Female
- Humans
- Mastectomy, Segmental/standards
- Medical Oncology/standards
- Neoplasm Staging
- Neoplasm, Residual
- Neoplasms, Second Primary/prevention & control
- Radiation Oncology/standards
- Radiotherapy, Adjuvant/methods
- Radiotherapy, Adjuvant/standards
- Retrospective Studies
- Societies, Medical
- United States
Collapse
Affiliation(s)
- Meena S Moran
- Department of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut
| | - Stuart J Schnitt
- Department of Pathology, Harvard Medical School, Boston, Massachusetts
| | - Armando E Giuliano
- Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California
| | - Jay R Harris
- Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts
| | - Seema A Khan
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Janet Horton
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
| | - Suzanne Klimberg
- Department of Surgery, University of Arkansas for Medical Sciences, Fayetteville, Arkansas
| | | | - Gary Freedman
- Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
| | - Nehmat Houssami
- School of Public Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | | | - Monica Morrow
- Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
| |
Collapse
|
20
|
Furet E, Peurien D, Fournier-Bidoz N, Servois V, Reyal F, Fourquet A, Rouzier R, Kirova YM. Plastic surgery for breast conservation therapy: how to define the volume of the tumor bed for the boost? Eur J Surg Oncol 2014; 40:830-4. [PMID: 24726879 DOI: 10.1016/j.ejso.2014.03.009] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Revised: 02/18/2014] [Accepted: 03/13/2014] [Indexed: 11/27/2022] Open
Abstract
PURPOSE To describe the procedure of definition of the boost volume using pre- and post-operative computed tomography (CT) and surgical clips in the tumor bed after oncoplastic surgical procedure. PATIENTS AND METHODS Thirty-one consecutive breast cancer patients who underwent simple lumpectomy or oncoplastic surgery were studied. All of them underwent pre- and post-operative CT scan in treatment position to evaluate the planning target volume (PTV) boost volume and define the primary tumor (gross tumor volume (GTV)) and tumor bed zones (CTV), with an overall margin of 5 mm in lateral and 10 mm in craniocaudal directions, corresponding to localization and setup uncertainties. RESULTS Thirteem patients underwent simple lumpectomy and 18 oncoplastic surgery. The volumetric analysis showed that the intersection between GTV and CTV clips was significantly higher in patients with three and more clips (28.4% vs 3.14%; p < 0.001). In the case of patients with oncoplastic surgery, more than three clips were needed to define the tumor bed volume with accuracy. The number of clips was directly related to the exact definition of the boost volume. CONCLUSIONS The use of more than three clips allows better definition of the PTV boost volume after oncoplastic surgical procedure.
Collapse
Affiliation(s)
- E Furet
- Department of Radiation Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France
| | - D Peurien
- Department of Radiation Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France
| | - N Fournier-Bidoz
- Department of Radiation Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France
| | - V Servois
- Department of Radiology, Institut Curie, Paris, France
| | - F Reyal
- Department of Surgical Oncology, Institut Curie, Paris, France
| | - A Fourquet
- Department of Radiation Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France
| | - R Rouzier
- Department of Surgical Oncology, Institut Curie, Paris, France
| | - Y M Kirova
- Department of Radiation Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
| |
Collapse
|
21
|
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014; 32:1507-15. [PMID: 24516019 DOI: 10.1200/jco.2013.53.3935] [Citation(s) in RCA: 281] [Impact Index Per Article: 28.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Controversy exists regarding the optimal margin width in breast-conserving surgery for invasive breast cancer. METHODS A multidisciplinary consensus panel used a meta-analysis of margin width and ipsilateral breast tumor recurrence (IBTR) from a systematic review of 33 studies including 28,162 patients as the primary evidence base for consensus. RESULTS Positive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with a two-fold increase in the risk of IBTR compared with negative margins. This increased risk is not mitigated by favorable biology, endocrine therapy, or a radiation boost. More widely clear margins do not significantly decrease the rate of IBTR compared with no ink on tumor. There is no evidence that more widely clear margins reduce IBTR for young patients or for those with unfavorable biology, lobular cancers, or cancers with an extensive intraductal component. CONCLUSION The use of no ink on tumor as the standard for an adequate margin in invasive cancer in the era of multidisciplinary therapy is associated with low rates of IBTR and has the potential to decrease re-excision rates, improve cosmetic outcomes, and decrease health care costs. J Clin Oncol 32. 2014 American Society of Clinical Oncology®, American Society for Radiation Oncology®, and Society of Surgical Oncology®. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology.
Collapse
Affiliation(s)
- Meena S Moran
- Meena S. Moran, Yale University School of Medicine, New Haven, CT; Stuart J. Schnitt and Jay R. Harris, Harvard Medical School, Boston, MA; Armando E. Giuliano, Cedars Sinai Medical Center, Los Angeles, CA; Seema A. Khan, Northwestern University Feinberg School of Medicine, Chicago, IL; Janet Horton, Duke University Medical Center, Durham, NC; Suzanne Klimberg, University of Arkansas for Medical Sciences, Fayetteville, AR; Mariana Chavez-MacGregor, University of Texas MD Anderson Cancer Center, Houston, TX; Gary Freedman, University of Pennsylvania School of Medicine, Philadelphia, PA; Nehmat Houssami, School of Public Health, University of Sydney Medical School, Sydney, New South Wales, Australia; Peggy L. Johnson, Susan G. Komen Advocate in Science, Wichita, KS; and Monica Morrow, Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Ann Surg Oncol 2014; 21:704-16. [DOI: 10.1245/s10434-014-3481-4] [Citation(s) in RCA: 275] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2013] [Indexed: 11/18/2022]
|
23
|
|
24
|
Giard S, Cutuli B, Antoine M, Barreau B, Besnard S, Bonneterre J, Campone M, Ceugnard L, Classe JM, Cohen M, Dohoullou N, Fourquet A, Guinebretière JM, Hennequin C, Leblanc-Onfroy M, Levy L, Mazeau-Woynar V, Mouret Reynier MA, Rousseau C, Verdoni L. Les recommandations nationales françaises de prise en charge du cancer du sein infiltrant. ONCOLOGIE 2013. [DOI: 10.1007/s10269-013-2296-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
25
|
Chand MÈ, Rivera S, Hennequin C, Hannoun-Lévi JM, Quero L. [Brachytherapy of breast cancer]. Cancer Radiother 2013; 17:125-9. [PMID: 23453755 DOI: 10.1016/j.canrad.2013.01.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2013] [Accepted: 01/17/2013] [Indexed: 10/27/2022]
Abstract
For breast cancer, interstitial brachytherapy remains an accurate irradiation technique for delivering a high dose (increasing the local control) in a small volume (decreasing the toxicity). In this article, we present the technical data related to the breast brachytherapy proceeding, from the implantation of the vectors to the treatment itself, including the planning. The different indications of breast brachytherapy include all the breast irradiations focusing on the initial tumour bed (partial irradiation of the breast), such as boost, accelerated and partial breast irradiation (APBI) and second conservative radiosurgical treatment in case of ipsilateral in-breast recurrence. The results in terms of efficacy and toxicity are presented for each indication. Interstitial breast brachytherapy, performed according with the standard rules, remains a major technique for breast cancer treatment.
Collapse
Affiliation(s)
- M-È Chand
- Département de radiothérapie oncologique, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice, France
| | | | | | | | | |
Collapse
|
26
|
Doré M, Hennequin C. Séquelles esthétiques de la radiothérapie adjuvante dans le traitement conservateur du cancer du sein localisé. Cancer Radiother 2012; 16:462-9. [DOI: 10.1016/j.canrad.2012.05.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2012] [Accepted: 05/23/2012] [Indexed: 01/07/2023]
|
27
|
Besnard S, Cutuli B, Fourquet A, Giard S, Hennequin C, Leblanc-Onfroy M, Mazeau-Woynar V, Verdoni L. [Radiotherapy of invasive breast cancer: French national guidelines]. Cancer Radiother 2012; 16:503-13. [PMID: 22921978 DOI: 10.1016/j.canrad.2012.07.181] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Accepted: 07/13/2012] [Indexed: 10/28/2022]
Abstract
The French National Cancer Institute (INCa) and Société française de sénologie et pathologie mammaire (SFSPM), in collaboration with a multidisciplinary experts group, have published the French national clinical practice guidelines on a selection of 11 currently debated questions regarding the management of invasive breast cancer. Those guidelines are based on a comprehensive analysis of the current published evidence dealing with those issues, secondly reviewed by 100 reviewers. Radiotherapy was concerned by five of the 11 questions: indications for the boost after whole gland irradiation; hypofractionated radiotherapy; partial breast irradiation; indications for mammary internal nodes irradiation, and indications of radiotherapy after neo-adjuvant chemotherapy.
Collapse
Affiliation(s)
- S Besnard
- Département recommandations et bon usage du médicament, direction des recommandations et de la qualité de l'expertise, Institut national du cancer, Boulogne-Billancourt, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
A Multi-Institutional Study of Feasibility, Implementation, and Early Clinical Results With Noninvasive Breast Brachytherapy for Tumor Bed Boost. Int J Radiat Oncol Biol Phys 2012; 83:1374-80. [DOI: 10.1016/j.ijrobp.2011.10.016] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2011] [Revised: 09/29/2011] [Accepted: 10/04/2011] [Indexed: 11/18/2022]
|
29
|
Mukesh M, Harris E, Jena R, Evans P, Coles C. Relationship between irradiated breast volume and late normal tissue complications: a systematic review. Radiother Oncol 2012; 104:1-10. [PMID: 22682540 DOI: 10.1016/j.radonc.2012.04.025] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Revised: 03/29/2012] [Accepted: 04/30/2012] [Indexed: 12/25/2022]
Abstract
The concept of radiation dose-volume effect has been exploited in breast cancer as boost treatment for high risk patients and more recently in trials of Partial Breast Irradiation for low risk patients. However, there appears to be paucity of published data on the dose-volume effect of irradiation on breast tissue including the recently published report on Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC). This systematic review looks at the current literature for relationship between irradiated breast volume and normal tissue complications and introduces the concept of dose modulation.
Collapse
Affiliation(s)
- Mukesh Mukesh
- Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
| | | | | | | | | |
Collapse
|